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ABSTRACT
Objective Gut homing of lymphocytes via adhesion
molecules has recently emerged as new target for
therapy in IBDs. We aimed to analyse the in vivo homing
of effector (Teff ) and regulatory (Treg) T cells to the
inﬂamed gut via α4β7 and G protein receptor GPR15.
Design We assessed the expression of homing
receptors on T cells in peripheral blood and inﬂamed
mucosa. We studied the migration pattern and homing
of Teff and Treg cells to the inﬂamed gut using intravital
confocal microscopy and FACS in a humanised mouse
model in dextran sodium sulfate-treated NSG (NOD.Cg-
Prkdcscid-Il2rgtm1Wjl/SzJ) mice.
Results Expression of GPR15 and α4β7 was
signiﬁcantly increased on Treg rather than Teff cells in
peripheral blood of patients with UC as compared with
Crohn’s disease and controls. In vivo analysis in a
humanised mouse model showed augmented gut
homing of UC Treg cells as compared with controls.
Moreover, suppression of UC (but not control) Teff and
Treg cell homing was noted upon treatment with the
α4β7 antibody vedolizumab. In contrast, siRNA blockade
of GPR15 had only effects on homing of Teff cells but
did not affect Treg homing in UC. Clinical vedolizumab
treatment was associated with marked expansion of UC
Treg cells in peripheral blood.
Conclusions α4β7 rather than GPR15 is crucial for
increased colonic homing of UC Treg cells in vivo, while
both receptors control UC Teff cell homing. Vedolizumab
treatment impairs homing of UC Treg cells leading to
their accumulation in peripheral blood with subsequent
suppression of systemic Teff cell expansion.
INTRODUCTION
A key feature of the inﬂammatory response in IBD
(Crohn’s disease (CD) and UC) is the rapid recruit-
ment of leucocytes from the blood stream to the
intestine via cell adhesion and transmigration
through blood-vessel walls.1 2 Consistently, marked
lymphocyte accumulation in the mucosa is one of
the histological hallmarks of IBD where these cells
are exposed to antigen presentation via antigen pre-
senting cells (APCs) such as dendritic cells and
macrophages.3–6 Encounters with cognate antigen
triggering of T cell receptor signalling lead to
shutdown of migratory T cell activity to allow
T cell priming and subsequent polarisation.7 8
Subsequently, mucosal T cells rapidly migrate to the
regional lymph nodes and ﬁnally reach the systemic
circulation via the thoracic duct. Antigen
Signiﬁcance of this study
What is already known on this subject?
▸ The adhesion molecule α4β7 has recently
emerged as a new target for therapy in
patients with IBDs.
▸ The monoclonal antibody vedolizumab
targeting α4β7 has been used successfully for
clinical therapy of Crohn’s disease and UC.
▸ GPR15 has recently been identiﬁed as a G
protein-coupled homing receptor that controls
homing of regulatory T (Treg) cells to the colon
in mice.
What are the new ﬁndings?
▸ Expression of α4β7 and GPR15 on human
regulatory FoxP3+ T cells is differentially
regulated by cytokines and both markers are
upregulated on Treg cells in UC.
▸ In vivo homing of Treg cells from patients with
UC to the inﬂamed colon in humanised mice is
augmented as compared with Treg cells from
controls.
▸ Targeting of adhesion molecule function by
vedolizumab did not affect homing of Treg cells
from controls yet revealed that α4β7 rather
than GPR15 is crucial for controlling homing of
Treg cells of patients with UC to the inﬂamed
colon in vivo, while both molecules are
involved in Teff cell homing in UC.
▸ Clinical vedolizumab therapy results in
accumulation of Treg cells in peripheral blood
of patients with UC.
How might it impact on clinical practice in
the foreseeable future?
▸ Analysis of human T cell homing in vivo using
humanised mice might be used to evaluate
upcoming antiadhesion therapies and to study
adoptive transfer systems for Treg cell based
therapy of IBD.
▸ GPR15 emerges as a new therapeutic target for
blocking Teff cell homing in IBD.
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experienced T cells can again enter into the gut mucosa by a
speciﬁc homing process that is tightly controlled by regulatory
molecules on the T cell surface and their ligands on intestinal
endothelial cells.
Gut homing and interstitial migration are governed by a
complex network of cell-intrinsic and cell-extrinsic factors that
ensure the proper positioning of immune cells in the context of
the local microenvironment.9 Hereby, mucosal homing of
T cells is controlled by regulatory molecules on T cells and
endothelial cells such as PSGL-1, ICAM-1 and LFA-1 as well as
by chemokines and their speciﬁc receptors that orchestrate a
multistep adhesion cascade involving tethering, rolling and stick-
ing of T cells.10 11 Studies in recent years have identiﬁed that
targeting of such mucosal T cell homing may be relevant for
therapy in IBD. This is particularly true for the integrin α4β7
that is expressed on the surface of gut-tropic effector lympho-
cytes. To allow intestinal imprinting, expression of α4β7 on
T cells is induced by T cell interaction with CD103 (integrin αE)
expressing mucosal dendritic cells that produce the vitamin A
metabolite retinoic acid via the enzyme retinaldehyde dehydro-
genase 2.12 Homing of α4β7 expressing T cells is mediated by
the speciﬁc interaction between α4β7 and its ligand
MAdCAM-1, which is expressed under steady state conditions
by gut endothelial cells.13
Although β7 integrins have recently been shown to control
homing of innate immune cells with tolerogenic potential,14
several studies revealed that blockade of the α4β7/MAdCAM-1
system can be used to inhibit T cell-dependent experimental
mucosal inﬂammation in vivo. Speciﬁcally, studies in murine
models of chronic intestinal inﬂammation demonstrated that
neutralising antibodies to α4, α4β7 and MAdCAM-1 prevent
the entry of CD4+ T cells to the intestinal mucosa and can be
used to suppress activity of mucosal inﬂammation.13 15–19
Moreover, treatment with the α4 blocker natalizumab was suc-
cessfully used for clinical therapy of patients with IBD.20 21
Unfortunately, some patients developed JC virus-related progres-
sive multifocal leucoencephalopathy probably due to blockade
of α4β1-dependent lymphocyte homing to the brain.22
Therefore, the α4β7 speciﬁc antibody vedolizumab was devel-
oped and resulted in signiﬁcant suppression of mucosal inﬂam-
mation in patients with CD and UC.23 24 This beneﬁcial effect
is probably due to internalisation of α4β7 on lymphocytes upon
vedolizumab binding that prevents MAdCAM-1-dependent gut
homing to induce intestinal immunosuppression.25 26
Furthermore, the β7 blocker etrolizumab targeting α4β7 and
αEβ7 integrins has been successfully tested in clinical studies in
UC27 28 suggesting that blockade of adhesion molecules on
immune cells may be of broad relevance for therapy of IBD.
In spite of these promising results on blockade of homing of
effector Tcells (Teff ), however, little is known about the mechan-
isms that control homing of human regulatory T (Treg) cells to
the inﬂamed bowel. Treg cells have been previously shown to
suppress Teff cell activity in the inﬂamed IBD mucosa29–31 and
their potential functional relevance has been suggested by clinical
pilot studies using adoptive transfer of expanded Treg cells in
patients with IBD in vivo.32 Interestingly, a recent study in mice
identiﬁed the G protein receptor GPR15 as a speciﬁc regulator of
Treg cell homing in the gut33 suggesting that Treg homing may
differ from homing of Teff cells. Moreover, GPR15 controlled
Treg homing to the colon rather than the small intestine33 raising
the possibility that Treg homing in humans may vary among dif-
ferent intestinal target areas.
To study homing of Treg cells, we have developed a new
system for assessment of homing of human T cells to the
inﬂamed bowel in vivo by using humanised mice. We noted that
α4β7 rather than GPR15 is crucial for colonic homing of UC
Treg cells in vivo, while both receptors control Teff homing.
The relevance of this ﬁnding was underlined by the observation
that clinical vedolizumab treatment in patients with UC leads to
signiﬁcant reduction of the blood Teff/Treg ratio in this disease.
Our ﬁndings suggest new avenues for future research on
mechanisms controlling in vivo homing of human T cells from
patients with IBD.
METHODS
Patients with IBD
To determine the expression of adhesion molecules on T cells in
humans, peripheral blood and colonic samples from patients
with IBDs and controls were analysed (see online supplementary
table S1). In these studies, colonic specimens from patients with
CD and UC were studied and compared with samples from con-
trols, as previously described.34 Gut samples were obtained
from areas of active disease of resected specimens or biopsies
from patients with CD and UC. The control group consisted of
patients without IBD that underwent colonic resections or
routine colonoscopy. In addition, blood samples were obtained
from patients with CD and UC as well as from healthy controls.
Some patients with UC were treated with vedolizumab (300 mg
by intravenous infusion at weeks 0, 2 and 623) before blood
collection, as speciﬁed in Results.
Immunohistochemistry in patients with IBD and controls
Cryosections from gut specimens of controls and patients with
IBD were used for immunohistochemistry. Tissues were ﬁxed in
4% paraformaldehyde, followed by sequential incubation with
avidin/biotin-blocking reagent (Vector Laboratories) and protein-
blocking reagent (Roth) to suppress unspeciﬁc background stain-
ing. Sections were incubated with primary antibodies speciﬁc for
human CD4 (RPA-T4, BD Pharmingen), CD4-biotin (RPA-T4,
Biolegend), CD8 (RPA-T8, BD Pharmingen), GPR15 (poly-
clonal, Bioss), FoxP3 (236A/E7, eBioscience) or α4β7 (vedolizu-
mab, Entyvio, Takeda). Furthermore, some sections were
incubated with appropriate isotype matched control antibodies
or without primary antibody as negative controls. Subsequently,
samples were incubated with secondary antibodies (Vectorlabs
and Jackson Immuno Research) followed by incubation with
streptavidin-conjugated Dylight 488 (Biolegend). Nuclei were
counterstained with Hoechst dye (molecular probes) before ﬁnal
analysis by ﬂuorescence and confocal microscopy (Leica SP8 or
Leica SP5 Microscope). Positive cells in 6–10 high power ﬁelds
were subsequently counted in all patients per condition. In some
images an inset of a higher magniﬁcation was included to better
identify the stained nuclei.
Isolation and ﬂow cytometric analysis of human blood and
lamina propria mononuclear cells
Peripheral blood mononuclear cells (PBMCs) from patients with
IBD and controls were isolated as previously described.34 35 For
FACS analysis of Treg cells, we ﬁrst excluded duplicated cells
(FSC-H/FSC-A) followed by gating on the T lymphocytes popu-
lation in the forward sideward scatter (SSC-A/FSC-A).
Afterwards we gated on CD4+ T cells. FoxP3+ CD4+ T cells
were deﬁned as Treg cells. Isolation of CD4+CD25+, CD4
+CD25− and CD4+CD25+CD127dim/− Teff or Treg cells
was performed by using the human CD4+CD25+ or CD4
+CD25+CD127dim/− Treg Cell Isolation Kits (Miltenyi Biotec)
according to manufacturer’s instructions. For GPR15 analysis
human CD4+ T cells, CD4+CD25+ T cells and CD4+CD25−
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T cells were stained with an anti-GPR15 antibody (R&D
systems), followed by an incubation with a speciﬁc mouse sec-
ondary IgG2b APC labelled antibody (R&D systems). In add-
ition, speciﬁc labelled antibodies against α4-integrin (FITC,
MZ18-24A9, Miltenyi Biotec), β7-integrin (PerCPcy5.5, FIB27,
Biolegend), CD4 (Paciﬁc Blue, VIT4, Miltenyi Biotec), CCR9
(PeCy7, L053E8, Biolegend), CCR5 (Alexa Fluor 700/647,
HEK/1/85a, Biolegend), CTLA-4 (PeCy7, L3D10, Biolegend),
GITR (APC, 621, Biolegend), CD25 (FITC, M-A251,
Biolegend), CD127 (Paciﬁc Blue, A019D5, Biolegend) or FoxP3
(Pe, 236A/E7, eBioscience), were used along with the isotype
control antibodies PerCP/cy5.5 rat IgG2a (Biolegend), Alexa
Fluor 700 rat IgG2a (Biolegend), Alexa Fluor 647 Mouse
IgG2a, Pe/Cy7 mouse IgG2a (Biolegend), mouse IgG2b
(Biolegend), FITC mouse IgG2b (Miltenyi Biotech) and Pe
mouse IgG1 (eBioscience). For intracellular staining of FoxP3,
cells were ﬁxed and permeabilised with the Foxp3/Transcription
Factor Staining Buffer Set (eBioscience). After washing, cells
were analysed by ﬂow cytometry (LSR Fortessa, BD).
Human T cell stimulation with cytokines and short-chain
fatty acids
Isolated CD4+ T cells were cultured in RPMI medium 1640
(Gibco) containing 10% FCS (Pan Biotech) and 1% penicillin/
streptocmycin (Biochrom) for 3 days in the presence of recombin-
ant interleukin (IL) 6 (20 ng/mL Immunotools), IL-7 (10 ng/mL,
Immunotools), IL-9 (10 ng/mL, Immunotools), IL-13 (25 ng/mL,
Immunotools), IL-21 (10 ng/mL, Immunotools), IL-33 (10 ng/mL,
Biolegend), TGF-ß1 (20 ng/mL, R&D Systems), butyric acid
(Roth), propionic acid (Roth), isobutyric acid (abcr), formic acid
(Merck) or medium alone. Cells were stimulated with anti-human
CD3 (OKT3, eBioscience) and anti-human CD28 (CD28.2, BD
Pharmingen) at a ﬁnal concentration of 1 μg/mL.
Human T cell proliferation and apoptosis assays
CD4+ T cells were treated with indicated concentrations of
vedolizumab and cultured for 3 days in the presence of anti-
human CD3, anti-human CD28 antibodies and recombinant
IL-2 (100 U/mL, Miltenyi Biotec). Staining was performed with
the CellTrace Violet Cell Proliferation Kit (Life Technologies).
Afterwards cell proliferation was analysed by ﬂow cytometry. In
some experiments, T cell apoptosis and necrosis was determined
by FACS using annexin V (FITC, Biolegend) and propidium
iodide (Pe, Bioscience).
MAdCAM-1/VCAM-1 adhesion assay
For adhesion assays, epoxy coated glass slides (Neolab) were
incubated overnight at 37°C with recombinant human or
murine MAdCAM-1 (both 5 mg/mL, R&D Systems) and human
(5 mg/mL, eBioscience) or murine VCAM-1 (5 mg/mL, R&D
Systems), dissolved in 20 mM HEPES (AMRESCO) and
150 mM NaCl. Afterwards slides were blocked with 5% BSA
for 2 h at 37°C, and 200.000 CD4+ T cells, Treg enriched CD4
+CD25+ cells or CD4+CD25− Teff cells, respectively, were
resuspended in adhesion buffer as previously described,36 added
to each well and allowed to adhere for 90 min at 37°C. In add-
ition, cells were treated with 1 mM MnCl2 and indicated con-
centrations of vedolizumab. Cells were washed with adhesion
buffer to remove non-adherent cells. Subsequently, cells were
ﬁxed in 4% paraformaldehyde followed by nuclear counterstain-
ing with Hoechst dye before ﬁnal analysis by ﬂuorescence and
confocal microscopy (Leica SP8 or Leica SP5 Microscope).
RNA induced gene silencing of GPR15
For downregulation of GPR15 in human T cells the Amaxa
Human T cell Nucleofector Kit was used, according to the man-
ufacturer’s instructions. 1×106 to 5×106 cells were treated with
either 300 ng siRNA for GPR15 (Qiagen) or AllStar negative
control (Qiagen). In addition, transfection with a GFP vector
was used as transfection control. Cells were incubated for at
least 4 h. Downregulation of GPR15 was analysed by real-time
PCR (forward primer: TCTCATGGGAGCGTT
GCATTT, reverse primer: CCACAGTCCTAGAGATGCTTCT)
and ﬂow cytometry.
Animals
The NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mouse strain
that lacks murine T cells, B cells and NK cells has been
described in detail elsewhere.37 Mice used in the experimental
dextran sodium sulfate (DSS) colitis model were between 7
weeks and 12 weeks of age. DSS colitis was induced as previ-
ously described38 using 1.5% DSS (MP Biomedicals) in the
drinking water over 1 week. All animals were housed under spe-
ciﬁc pathogen-free conditions. Experiments were performed
with permission of the government of Middle Franconia in
accordance with institutional guidelines.
Adoptive transfer of human cells and in vivo confocal
microscopy
For adoptive transfer human cells were labelled with CFSE
according to the manufacturer’s instructions (Life Technologies).
Mice were anaesthetised by intraperitoneal injection of keta-
mine/xylazine. Texas Red dextran (Life Technologies) was
injected into the tail vein to stain blood vessel structures. For
cell transfer the colon was prepared upon median laparotomy.
The ileocolic artery was identiﬁed and 1 million human T cells
or PBMCs were given by intra-arterial injection. In some experi-
ments, Hoechst dye was injected intravenously before cell trans-
fer to stain mouse cell nuclei and Texas Red dextran was
administered into the ileocolic artery together with the cells.
Additionally, some mice were given 6 mg Alexa Fluor
647-conjugated anti-CD31 antibody (390, Biolegend) by tail
vein injection 18 h before adoptive transfer of cells.
The colon was exteriorised and the colonic mucosa was posi-
tioned on a glass transparent petri dish. Images of the colon
were taken after the adoptive transfer with a confocal micro-
scope (SPM 8 or SPM 5 Leica). For detection 405 nm
(Hoechst), 488 nm (CFSE), 595 nm (Texas Red dextran) and
638 nm Laser (Alexa Fluor 647) were used. In some experi-
ments, 1 mg vedolizumab was injected into the tail vein 18 h
before adoptive transfer and additionally human T cells were
incubated with 100 mg/mL vedolizumab for 2 h before adoptive
transfer.
Maestro in vivo imaging
To monitor cell trafﬁcking, human T cells were stained with Q
Tracker 800 Cell Labeling Kit (Life Technologies) according to
the manufacturer’s instructions. Cells were injected into the tail
vein of NSG mice and images were acquired after 18 h (Maestro
in vivo imaging system, Perkin Elmer).
Isolation and analysis of lamina propria mononuclear cells
from NSG mice
T cell enriched lamina propria mononuclear cells (LPMCs) were
isolated from the colon of mice with the help of the lamina
propria dissociation kit (Miltenyi Biotec) according to the
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manufacturer’s guidelines.34 Mononuclear cells were separated
from epithelial cells using Percoll gradient (Biochrom). Cells
were counted, washed and stained for FACS analysis as
described in the results. Upon human T cell transfer, we usually
detected 100–1000 CFSE+ cells in the murine lamina propria
by FACS.
Immunohistochemistry of murine colonic tissue
Staining of murine cryosections was performed with primary
antibodies against MAdCAM-1 (MECA367, Bio-Rad company)
and CD31 (polyclonal, Abcam). Tissues were ﬁxed in 4% paraf-
ormaldehyde, followed by treatment with protein-blocking
reagent (Roth) to suppress unspeciﬁc background staining.
Furthermore, some sections were incubated without primary
antibodies as negative controls. Subsequently, samples were
incubated with secondary antibodies which were directly
labelled with ﬂuorochromes (Vectorlabs). Nuclei were counter-
stained with Hoechst dye (molecular probes) before ﬁnal ana-
lysis by confocal microscopy (Leica SP8 Microscope).
Statistics
Statistical differences between groups in human samples were
determined by using ANOVA. Where necessary, correction for
multiple testing by the Bonferroni method was applied. For
murine data the Student’s t test was used. p Values <0.05 were
considered statistically signiﬁcant and identiﬁed with asterisks
(*<0.05, **<0.01, ***<0.001). Results are expressed as mean
values. The error bars in histogram ﬁgures represent SEM.
RESULTS
GPR15 and α4β7 expression on FoxP3+ Treg cells is induced
in patients with UC
Although functionally active FoxP3+ Treg cells have been
demonstrated in the peripheral blood and the mucosa of
patients with UC,29 30 39 their expression pattern of homing
markers has not been previously studied in detail. To address
this question, we analysed expression of the integrin α4β7 that
has been previously shown to control gut homing of T cells via
its interaction with MAdCAM-1.23 40 Accordingly, we per-
formed quantitative FACS analysis of α4β7 integrin expression
and mean ﬂuorescence intensity on FoxP3+ CD4+ regulatory
T cells from peripheral blood of patients with UC and CD and
healthy controls (n=106) and compared the results with those
of FoxP3− CD4+ Teff cells (ﬁgure 1A). In patients with IBD,
expression of α4β7 was more frequently detected on Treg cells
compared with Teff cells. Furthermore, there was a signiﬁcant
induction of α4β7 integrin expression and mean ﬂuorescence
intensity on Treg cells in active UC as compared with controls,
while a signiﬁcant reduction of α4β7 integrin levels was noted
on CD and UC Teff cells (ﬁgure 1A).
Next, we addressed the expression of additional homing recep-
tors such as CCR5 and CCR9 that have been previously demon-
strated to be expressed on T cells in IBD.41 42 In patients with
CD, patients with UC and controls, it was found that signiﬁcantly
more Treg cells expressed CCR5 than Teff cells (ﬁgure 1B).
However, no signiﬁcant differences in CCR5 expression on Treg
cells were noted between patients with UC, patients with CD and
controls. Similarly to CCR5, CCR9 expression was more fre-
quently detected on Treg cells than Teff cells (ﬁgure 1C). No sig-
niﬁcant differences in CCR9 levels on Treg cells were observed
between UC and control groups. Finally, we addressed the
expression of GPR15, a recently described homing receptor for
the murine colon,33 on human Treg cells. We detected a higher
percentage of GPR15+ Treg cells as compared with GPR15+
Teff cells in patients with CD, patients with UC and controls
(ﬁgure 1D). Interestingly, a signiﬁcant induction of GPR15
expression was seen on Treg cells in patients with UC and
patients with CD as compared with controls, although the
highest levels of GPR15 on Treg cells were noted in UC.
In subsequent experiments, we addressed the question whether
speciﬁc combinations of the homing receptors α4β7 integrin,
CCR9 and GPR15 are expressed on the surface of Treg cells in
patients with IBD and controls. Small subgroups of Treg and Teff
cells expressing combinations of two or three homing receptors
were noted. A signiﬁcant induction of α4β7+/GPR15+ Treg and
α4β7+/GPR15+/CCR9+ Teff cells was observed in patients with
UC as compared with controls, whereas no signiﬁcant differences
were detected between patients with CD and controls (ﬁgure 1E).
In contrast, signiﬁcantly fewer Teff cells expressing α4β7 integrin
plus CCR9 were detected in patients with UC as compared with
controls.
In summary, these ﬁndings suggested relatively high expres-
sion of gut homing receptors on Treg cells in UC, although
most UC Treg cells expressed only one of the key homing recep-
tors α4β7, CCR9 and GPR15. In particular, Treg cells in UC
expressed more frequently α4β7 integrins and the colon homing
receptor GPR15 than Treg cells from controls consistent with
the idea that homing of Treg cells via these receptors might be
augmented in UC.
Expression of GPR15 and α4β7 in the inﬂamed gut in IBD and
regulation of their expression on regulatory FoxP3+ T cells
As these ﬁndings were consistent with the idea that GPR15 and
α4β7 control homing of Treg cells to the inﬂamed gut in UC,
we next determined the presence of mucosal T cells bearing
these surface receptors by immunohistochemistry. We observed
that many α4β7 expressing T cells are present in the inﬂamed
tissue in patients with CD and patients with UC and the
number of these cells was signiﬁcantly increased in patients with
IBD as compared with controls (ﬁgure 2A). As the number of
CD4+ T cells negative for α4β7 was only slightly and not sig-
niﬁcantly higher in UC and CD, this raised the possibility that
α4β7 is a marker for the excess CD4+ cellular colonic inﬁltrate
in IBD. Furthermore, GPR15 was mainly expressed on mucosal
CD4+ T cells rather than CD8+ T cells in patients with IBD
and controls (ﬁgure 2B–D). A signiﬁcant induction of GPR15
expressing FoxP3− Teff cells was detected in patients with CD
and patients with UC as compared with controls consistent with
the idea that this receptor may control homing of these cells to
the colon. Moreover, only very few GPR15+/FoxP3+ expres-
sing cells were observed in patients with CD and controls
(ﬁgure 2C). Similarly, in spite of the higher percentage of
GPR15 expressing blood Treg cells in UC, very few or no
GPR15+ FoxP3+ T cells were noted in this disease suggesting
that either homing of Treg cells is independent of GPR15 or
that GPR15 expression is rapidly lost upon gut homing of these
cells.
To gain further insights into the signalling mechanisms con-
trolling GPR15 expression, we co-incubated Treg cells with
various bacterial metabolites and regulatory cytokines (ﬁgure
2E). Whereas isobutyric acid and propionic acid had no signiﬁ-
cant effects on GPR15 expression in FoxP3+ Treg cells, butyric
acid led to a signiﬁcant induction of GPR15 levels. In contrast,
such effect of butyric acid was not observed on FoxP3− Teff cells
suggesting that this microbe-derived short-chain fatty acid specif-
ically controls GPR15 levels in Treg cells. In contrast to butyric
acid, formic acid, a metabolite formed by microorganisms in the
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colon during initial dietary fermentation,43 signiﬁcantly sup-
pressed GPR15 expression on Treg cells.
Next, we looked at the effects of proinﬂammatory and anti-
inﬂammatory cytokines on GPR15 expression. We observed that
the proinﬂammatory cytokine IL-7, that is present in the
inﬂamed mucosa in UC34 31 44 45 results in suppression of
GPR15 expression on Treg and Teff cells, while IL-9 suppressed
GPR15 only on Treg cells (ﬁgure 2F). In contrast to GPR15, the
integrin α4β7 was induced on Treg cells by the proinﬂammatory
cytokines IL-6 and IL-21 in the presence of TGF-β1. However,
IL-7 and IL-7 plus TGF-β1 resulted in marked induction of
α4β7 on Teff cells. Taken together, these ﬁndings suggested that
several proinﬂammatory cytokines present in the inﬂamed UC
mucosa speciﬁcally suppress the expression of GPR15 on Treg
cells, while proinﬂammatory cytokines may induce α4β7 expres-
sion on these cells in the presence of TGF-β1.
Figure 1 The expression of α4β7 integrins and GPR15 is upregulated on regulatory FoxP3+ T cells in UC. (A) Upper panels: Representative FACS
analysis of α4β7 integrin expression on FoxP3− CD4+ effector T (Teff ) cells and FoxP3+ CD4+ regulatory T cells (Treg) from peripheral blood in
patients with UC as compared with patients with Crohn’s disease (CD) and controls. Isotype control staining is shown additionally (right panels).
The percentage of α4β7 integrin expressing cells is indicated. Lower right panels: Quantitative FACS analysis of β7 integrin mean ﬂuorescence
intensity (MFI) on FoxP3− CD4+ α4+ Teff cells and FoxP3+ CD4+ α4+ regulatory T cells from peripheral blood. Samples from patients with UC
(n=20), patients with CD (n=36) and controls (n=50) were used for analyses. Data represent ﬁndings from 106 patients and statistically signiﬁcant
differences are indicated (*p<0.05; **p<0.01; ***p<0.001). Lower left panels: Exemplary gating strategy used for FACS analysis of β7 integrin MFI.
(B–D) FACS analyses of CCR5 (B), CCR9 (C) and GPR15 (D) expression on FoxP3− CD4+ Teff cells and FoxP3+ CD4+ regulatory T cells from
peripheral blood. Samples from patients with UC, CD and controls were used for analyses. The percentage of positive cells is shown. Signiﬁcant
differences are indicated. (E) FACS analyses of FoxP3− CD4+ Teff cells and FoxP3+ CD4+ regulatory T cells from peripheral blood expressing two or
three adhesion molecules. Samples from patients with UC (n=7), patients with CD (n=10) and controls (n=17) were used for analyses. Statistically
signiﬁcant differences are indicated.
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A new humanised mouse model for in vivo analysis of T cell
homing to the inﬂamed gut
The above data were consistent with the idea that the gut
homing receptors α4β7 and GPR15 that were increasingly
expressed on blood UC Treg cells play a functional role in
driving this disease by controlling mucosal inﬂux of immune
cells. However, there are no satisfying systems to determine
homing of human Treg cells to the inﬂamed gut under in vivo
circumstances and thus to analyse the functional relevance of
human homing receptors in UC Treg cells. In order to develop a
model for assessment of in vivo homing, we decided to consider
a humanised mouse system based on the NSG (NOD.
Cg-Prkdcscid-Il2rgtm1Wjl/SzJ) mouse strain that lacks murine
T cells, B cells and NK cells.37 Before T cell transfer NSG mice
were treated with DSS for 1 week in drinking water to induce
colonic inﬂammation according to established protocols.38
Initial studies on the in vivo homing of adoptively transferred,
CFSE-labelled human cells in NSG mice showed that intraven-
ous delivery (tail vain or retro-orbital injection) of T cells or
PBMCs is not suitable for assessment of gut homing, as more
than 90% of the transferred human cells were retained in the
capillaries of the lung (ﬁgure 3A, B) probably due to the larger
size of human T cells (10–15 μm) as compared with mouse
T cells (7–8 μm). We therefore focused in subsequent studies on
the adoptive transfer of T cells from controls via the ileocolic
artery (ﬁgure 3C). Accordingly, CFSE-labelled cells were
Figure 1 Continued
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injected locally into the ileocolic artery followed by assessment
of T cell homing to the colon. In vivo confocal microscopy of
the murine colon with simultaneous vessel imaging using Texas
Red dextran showed homing of CFSE-labelled human PBMCs
and CD4+ T cells from controls and patients with UC to the
inﬂamed gut (ﬁgure 3D). Migration and entering of labelled
cells into the mucosa could be detected 10–20 min after injec-
tion. Furthermore, intravenous injection of Hoechst dye prior
to adoptive cell transfer resulted in ﬂuorescent staining of the
mouse cell nuclei and confocal microscopy demonstrated CFSE
+ human cells from controls and patients with UC that had
migrated from the vessels to the gut mucosa (ﬁgure 3E).
Consistently, we were able to show homing after in vivo staining
of the mouse endothelium by intravenous injection of a
ﬂuorescent-labelled anti-CD31 antibody instead of vessel
staining with Texas Red dextran (ﬁgure 3F). By taking sequential
images, the migratory movement of homing cells could be illu-
strated (ﬁgure 3G, online video). Finally, homing of labelled
cells to the mucosa could be conﬁrmed by immunoﬂuorescence
analysis of labelled T cells by using ex vivo staining analysis of
gut cryosections (ﬁgure 3H). Taken together, these observations
suggested that the T cell transfer model in NSG mice is suitable
for analysis of gut homing in vivo.
To determine the relevance of mucosal inﬂammation for
human cell homing in NSG mice, we performed additional
experiments in the presence or absence of DSS treatment.
As shown in ﬁgure 3I, homing of PBMCs to the gut was mark-
edly dependent on the presence of mucosal inﬂammation and
more cells entered into the mucosa in the presence of DSS treat-
ment as compared with uninﬂamed tissue. As it is likely that
Figure 1 Continued
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these differences were due to changes in the expression of
ligands for homing receptors on endothelial cells, we next deter-
mined expression of the α4β7 ligand MAdCAM-1 in NSG mice.
We observed that DSS treatment led to marked upregulation of
colonic MAdCAM-1 expression as compared with untreated
NSG mice (ﬁgure 3J). Moreover, double staining analysis
revealed that CD31 expressing colonic endothelial cells express
MAdCAM-1 (ﬁgure 3K) consistent with the idea that
Figure 2 Lamina propria CD4+ effector T (Teff ) cells but not mucosal regulatory T (Treg) cells express GPR15 in patients with UC. (A) Cryosections
of colonic specimens were incubated with α4ß7 integrin and CD4+ antibodies followed by detection with secondary antibodies. Nuclei were
counterstained with Hoechst dye. The number of double (arrows) and single positive cells per high power ﬁeld was counted. Data represent mean
values±SEM per high power ﬁeld. Double staining analysis for CD4 and α4ß7 integrin showed a signiﬁcant increase of double positive cells in
patients with IBD as compared with controls. Data represent results of four independent experiments (n=18). (B) Cryosections of colonic specimens
were incubated with GPR15 and CD4+ antibodies followed by detection with secondary antibodies. Cells were counterstained with Hoechst dye. The
number of double (arrows) and single positive cells per high power ﬁeld was counted. Data represent mean values±SEM per high power ﬁeld.
Double staining analysis for CD4 and GPR15 showed a signiﬁcant increase of double positive cells in patients with IBD as compared with controls.
Data represent results of three independent experiments (n=13). (C) Double staining analysis of FoxP3 and GPR15 in patients with IBD and controls
(n=19). Cryosections were incubated with FoxP3 and CD4 antibodies followed by counterstaining with Hoechst dye. Representative stainings are
shown. Data represent results of three independent experiments. Double positive cells were counted per high power ﬁeld and signiﬁcant differences
are indicated. FoxP3 expressing cells are highlighted by arrows. There was a signiﬁcant increase of mucosal GPR15+ FoxP3− Teff cells in IBD, while
little or no GPR15+ FoxP3+ mucosal Treg cells were found. (D) Double staining analysis of GPR15 and CD8 in patients with IBD and controls
(n=12). Cryosections were incubated with GPR15 and CD8 antibodies followed by counterstaining with Hoechst dye. Representative stainings are
shown. Data represent results of three independent experiments. Double positive cells were counted per high power ﬁeld and signiﬁcant differences
are indicated. There were only few GPR15+ mucosal CD8+ T cells in patients with IBD and controls. (E) Regulation of GPR15 expression by
microbial metabolites. CD4+ FoxP3+ Treg cells and CD4+ FoxP3− Teff cells were co-incubated with different concentrations of butyric acid,
isobutyric acid, formic acid and propionic acid for 3 days, as indicated. Subsequently, FACS analysis for expression of α4β7 and GPR15 was done.
Data represent four to eight independent experiments and statistically signiﬁcant differences are indicated. (F) Regulation of α4β7 and GPR15
expression by proinﬂammatory and anti-inﬂammatory cytokines. CD4+ FoxP3+ Treg cells and CD4+ FoxP3− Teff cells were co-incubated with
various regulatory recombinant cytokines for 3 days, as indicated. Subsequently, FACS analysis for expression of α4β7 and GPR15 was done. Data
represent three to seven independent experiments per group. Statistical analysis included correction for multiple testing by the Bonferroni method
and statistically signiﬁcant differences are indicated (*p<0.05; **p<0.01; ***p<0.001).
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augmented T cell homing to the colon during inﬂammation is
mediated by increased binding of T cell receptors to their
ligands on endothelial cells.
In vivo homing to the inﬂamed gut is augmented in regulatory
T cells from patients with UC as compared with controls
We next addressed the question whether increased expression of
homing receptors on Treg cells in patients with UC is associated
with changes in their homing capacities to the inﬂamed gut
in vivo. In initial experiments, we aimed at characterising the
CD4+CD25+ Treg enriched population we used for adoptive
transfer experiments (see online supplementary ﬁgure S1). By
using the human CD4+CD25+ isolation kit, high levels of
FoxP3 and low levels of CD127+ Tcells could be demonstrated.
Similarly, Treg enriched populations isolated with a kit based on
the markers CD4+CD25+CD127dim/- showed low levels of
CD127+ Tcells. The Treg enriched populations obtained via the
CD4+CD25+ and the CD4+CD25+CD127dim/- kits did not
Figure 2 Continued
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differ in the expression of the additional Treg markers CTLA-4
and GITR suggesting that both kits are suitable for enrichment of
human Treg cells from peripheral blood.
In subsequent studies, we analysed the homing capacities of
Treg enriched cells in vivo. Accordingly, we injected puriﬁed CFSE
+ Treg enriched CD4+CD25+ or CD4+CD25+CD127dim/-
T cells from patients with UC and controls into DSS-treated NSG
mice and monitored migration of T cells to the inﬂamed colon.
In vivo confocal imaging revealed augmented homing of Treg
enriched cells from patients with UC as compared with controls
(ﬁgure 4A, B). Consistently, FACS analysis of isolated lamina
propria mononuclear cells showed a marked increase in homing of
Treg enriched CFSE+ UC cells as compared with CFSE+ cells
from controls (ﬁgure 4C). Quantitative analysis demonstrated sig-
niﬁcant induction of gut homing in Treg enriched CFSE+ CD4+
CD25+ T cells in UC as compared with controls (ﬁgure 4D).
Figure 2 Continued
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Figure 3 A humanised mouse model for analysis of human T cell homing to the inﬂamed gut in vivo. (A) Analysis of cell trafﬁcking upon
intravenous transfer of human T cells into immunodeﬁcient NSG mice. Imaging of murine colon and lungs was performed 18 h after human T cell
transfer by Maestro imaging. Organs from NSG mice without human T cell transfer served as controls. (B) Representative immunoﬂuorescence of
murine colon and lungs after human T cell transfer in NSG mice. CFSE positive human T cells are highlighted by arrows. (C) Preparation of the
ileocolic artery for adoptive human cell transfer upon mini laparotomy (left panel). The ileocolic artery was prepared followed by ink injection (right
panel, insert) to demonstrate successful puncture. One representative experiment is shown. (D) Confocal in vivo microscopy 20 min after injection of
human peripheral blood mononuclear cells (PBMCs) or human CD4+ T cells from controls or patients with UC into the ileocolic artery in dextran
sodium sulfate (DSS)-treated NSG mice. Vessels were stained by Texas Red dextran. In vivo homing of CFSE-labelled human cells (arrows) to the
mucosa could be demonstrated. (E) Confocal in vivo microscopy after intravenous injection of Hoechst dye and injection of PBMCs or T cells together
with Texas Red dextran into the ileocolic artery. In vivo homing of CFSE-labelled human cells (arrows) to the mucosa could be demonstrated. Blue—
murine cells, green—human cells, red—blood vessels. (F) Confocal in vivo microscopy after intravenous injection of Hoechst dye and adoptive
transfer of CFSE-labelled human PBMCs via the ileocolic artery 18 h after intravenous injection of Alexa Fluor 647-labelled anti-mouse CD31 for
staining of endothelial cells (red colour). In vivo homing of human cells (arrows) to the mucosa could be demonstrated. (G) Sequential images taken
by in vivo confocal microscopy after injection of CFSE-labelled human PBMCs and Texas Red dextran into the ileocolic artery and prior intravenous
injection of Hoechst dye. The migratory movement of a homing cell from a vessel (yellow cell) to the mucosa (green mucosal cell) can be seen
(online video available). Blue—murine cells, red—blood vessels. (H) Immunoﬂuorescence analysis of colonic samples from DSS-treated NSG mice
upon transfer of CFSE-labelled human CD4+ T cells. Homing of human T cells to the inﬂamed mucosa could be seen 30 min after cell transfer.
Untreated mice served as negative control. (I) Upper panels: FACS analysis of lamina propria cells in DSS-treated or untreated NSG mice before cell
transfer and FACS analysis of labelled human PBMCs before cell transfer. Lower panels: Representative FACS analysis of lamina propria mononuclear
cells (LPMCs) and blood cells from NSG mice given human PBMCs in the presence or absence of DSS treatment. NSG mice without human cell
transfer served as negative control. One representative out of three experiments is shown. DSS treatment led to marked induction of homing of
human cells to the inﬂamed gut. (J) Analysis of expression of the α4β7 ligand MAdCAM-1 in the colon of NSG mice in the presence or absence of
DSS treatment. Nuclei were counterstained with Hoechst dye. DSS treatment resulted in upregulation of MAdCAM-1 expression in the colon. One
representative out of three experiments is shown. (K) Double staining analysis of MAdCAM-1 and CD31 in the colon and small intestine of NSG
mice in the presence or absence of DSS treatment. Colitis development caused an upregulation of MAdCAM-1 expression on endothelial cells
(yellow; arrows).
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Further analysis of FoxP3 expression on mucosal CFSE+ UC cells
showed an upregulation in the percentage of lamina propria cells
expressing the transcription factor FoxP3 as compared with
CFSE+ cells from controls (ﬁgure 4E) suggesting that regulatory
T cells from patients with UC expressing FoxP3 are enriched
during migration into the mucosa of NSG mice. These ﬁndings
suggested that Treg cells in UC display augmented expression of
gut homing markers associated with increased gut homing capaci-
ties as compared with Treg cells from controls.
Vedolizumab treatment suppresses homing of regulatory
T cells from patients with UC but not controls to the
inﬂamed gut in vivo
Although the α4β7 blocking antibody vedolizumab has recently
been used for the successful treatment of patients with UC,23
little is known about the effects of this antibody on human
Treg and Teff cell homing to the gut in vivo. We therefore
aimed to analyse the in vivo effects of vedolizumab on homing
of T cells to the inﬂamed colon. Accordingly, we studied ﬁrst,
Figure 3 Continued
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whether vedolizumab directly affects proliferation, apoptosis
or necrosis of CD4+ T cells. As shown in ﬁgure 5A–C,
vedolizumab had no direct effects on proliferation of T cells
from controls and patients with UC. Moreover, no effects on
apoptosis and necrosis of cells were noted. Finally, no differ-
ences between T cells from patients with UC and controls were
observed upon vedolizumab treatment. We next determined the
capacity of this antibody to block adhesion of CD4+ T cells in
vitro using MAdCAM-1 coated plates. These studies showed
that vedolizumab signiﬁcantly suppressed adhesion of human
CD4+ T cells from patients with UC and controls to
MAdCAM-1 (ﬁgure 5D). Surprisingly, CD4+ T cells from con-
trols displayed a greater afﬁnity to MAdCAM-1 than cells from
patients with UC. We therefore repeated these adhesion assays
comparing CD4+CD25+ Treg enriched cells and CD4+CD25
− Teff cells from controls and patients with UC. It was found
that adhesion of Teff cells to MAdCAM-1 was higher in controls
than in patients with UC (ﬁgure 5E), but vice versa for Treg
cells (ﬁgure 5F). This is line with the ﬂow cytometry data on
α4β7 expression on both cell types presented in ﬁgure 1.
Additionally, we used the adhesion assay technique to conﬁrm
that the previously demonstrated homology of integrin binding
Figure 3 Continued
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domains of human and murine MAdCAM-146 results in a cross-
species interaction of human CD4+ T cells and murine
MAdCAM-1 and VCAM-1, a less important ligand of α4β7.47
As expected, adhesion of human CD4+ T cells to the murine
ligands was lower as compared with the human ligands, but
with about 80% for murine MAdCAM-1 and about 70% for
Figure 4 Augmented homing of regulatory T (Treg) cells in UC. (A and B) In vivo confocal microscopy for analysis of homing of human CD4+CD25+
Treg cells (A) and CD4+CD25+CD127dim/- Treg cells (B) to the inﬂamed murine colon in NSG mice. NSG mice were treated with dextran sodium
sulfate (DSS) for 7 days to induce colitis followed by Treg cell transfer. The transfer of Treg enriched cells from patients with UC led to augmented
numbers of cells reaching the inﬂamed mucosa as compared with controls (arrows). In panel A one representative experiment out of ﬁve is shown.
Blue—murine cells, green—CFSE+ human cells, red—vessels. (C) Upper panels: FACS analysis of CFSE-labelled human CD4+CD25+ T cells from
controls and patients with UC before T cell transfer in DSS-treated NSG mice. Lower panels: FACS analysis of isolated lamina propria mononuclear cells
(LPMCs) from DSS-treated NSG mice after T cell transfer. Treg enriched cells were isolated from peripheral blood of patients with UC and controls
followed by adoptive transfer in NSG mice. Homing of UC Treg cells was augmented as compared with homing of Treg cells from controls. One
representative experiment out of ﬁve is shown. (D) Analysis of homing of CFSE-labelled Treg cell enriched CD4+CD25+ T cells from controls and
patients with UC in DSS-treated NSG mice. The fold-increase of UC T cell homing in relation to control T cell homing to the mucosa of DSS-treated NSG
mice is shown. Data represent ﬁndings from ﬁve independent experiments. Signiﬁcant differences are indicated (*p<0.05). (E) Quantitative analysis of
FoxP3 expression on CFSE-positive LPMCs from NSG mice by FACS analysis. The fold-increase of UC FoxP3+ Treg cell homing in relation to control
FoxP3+ Treg cell homing to the mucosa of DSS-treated NSG mice is shown. Data represent ﬁndings from ﬁve independent experiments. Statistically
signiﬁcant differences are indicated (**p<0.01).
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Figure 5 The α4β7 neutralising antibody vedolizumab suppresses binding of human CD4+ T cells from patients with UC to MAdCAM-1. (A)
Proliferation of puriﬁed blood human CD4+ T cells from controls or patients with UC in the presence or absence of vedolizumab after 3 days.
Proliferation was determined by FACS analysis of cell tracer violet. The data represent results of three to four samples per group. (B and C) Analysis
of apoptosis and necrosis in puriﬁed blood human CD4+ T cells in the presence or absence of vedolizumab after 3 days. The percentage of
apoptotic annexin V+/PI- cells and necrotic annexin V+/PI+ cells was determined by FACS analysis. The data represent results of three independent
experiments. (D – F) Analysis of cell adhesion to MAdCAM-1 in puriﬁed blood human CD4+ T cells (D), CD4+CD25− Teff cells (E) and Treg enriched
CD4+CD25+ cells (F) from patients with UC or controls in the presence or absence of vedolizumab. Glass slides were incubated with recombinant
human MAdCAM-1 followed by addition of T cells and washing. Vedolizumab led to a signiﬁcant suppression of human T cell binding to
MAdCAM-1 in controls and patients with UC. While adhesion of Teff cells was higher in controls, Treg adhesion was augmented in UC. Some
adherent cells are highlighted by arrows. Data are representative of three to ﬁve independent experiments. Statistically signiﬁcant differences are
indicated. (G) Comparison of human CD4+ T cell adhesion to slides coated with human and murine MAdCAM-1 as well as VCAM-1, respectively.
Human T cells showed a high level of adherence towards the murine ligands. Data are representative of three independent experiments. Statistically
signiﬁcant differences are indicated.
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murine VCAM-1 the relative adherence was still on very high
levels (ﬁgure 5G).
Next, we determined the capacity of vedolizumab to modu-
late homing of CD4+CD25− Teff cells to the inﬂamed gut in
vivo. Accordingly, we treated NSG mice and human Teff cells
with vedolizumab before T cell transfer. We found that vedolizu-
mab treatment had no signiﬁcant effect on T cell homing when
Teff cells from controls were used. In contrast, vedolizumab
inhibited the homing of Teff cells from patients with UC, as
determined by in vivo confocal microscopy (ﬁgure 6A).
Similarly, FACS analyses showed signiﬁcant inhibition of homing
of Teff cells from patients with UC but not controls to the
inﬂamed colon upon vedolizumab treatment (ﬁgure 6B, C) indi-
cating that this treatment markedly affects homing of UC Teff
cells in vivo. To assess the impact of GPR15 for colonic homing
of Teff cells, we suppressed GPR15 expression on UC Teff cells
by transfection with siRNA. As can be seen in ﬁgure 6D, E, this
knockdown was effective on mRNA and protein levels. In vivo
confocal microscopy and quantitative FACS analysis after adop-
tive transfer of accordingly treated Teff cells showed a signiﬁcant
reduction of homing of these cells to the inﬂamed gut (ﬁgure
6F, G). This ﬁnding could be conﬁrmed by adoptive transfer of
GPR15+ and GPR15− Teff cells that had been puriﬁed by
FACS sorting (ﬁgure 6H).
Figure 5 Continued
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Likewise, we explored the effect of vedolizumab on homing of
Treg enriched CD4+CD25+ cells in our humanised mouse
model. Again, homing of cells from controls was not affected by
vedolizumab treatment (ﬁgure 6I, J). On the contrary, in patients
with UC Treg homing was suppressed signiﬁcantly by vedolizu-
mab and even more markedly than in UC Teff cells (ﬁgure 6I, K).
In contrast to α4β7 blockade, suppression of GPR15 expression
on UC Treg cells via siRNA had no effect on homing of these
cells to the inﬂamed colon (ﬁgure 6L). Similarly, no difference in
homing was noted between GPR15+ and GPR15− UC Treg cells
(ﬁgure 6H) suggesting that α4β7 rather than GPR15 controls gut
homing of UC Treg cells in vivo. Although we have shown above,
that CD4+CD25+ Tcells represent a population highly enriched
with Treg cells, we aimed to conﬁrm our ﬁndings for vedolizu-
mab treatment with CD4+CD25+CD127dim/- Treg enriched
cells by adoptive transfer of accordingly isolated cells from con-
trols and patients with UC. We could show that homing of Treg
cells from controls was not altered by vedolizumab treatment,
while vedolizumab signiﬁcantly inhibited homing of Treg cells
from patients with UC to the inﬂamed mucosa (see online sup-
plementary ﬁgure S2).
The above ﬁndings suggested vedolizumab-induced blockade
of homing of UC Treg cells to the inﬂamed colon. To analyse
whether such inhibition of Treg homing leads to accumulation
Figure 5 Continued
Fischer A, et al. Gut 2015;0:1–24. doi:10.1136/gutjnl-2015-310022 17
Inﬂammatory bowel disease
of Treg cells in the peripheral blood, we studied in a ﬁnal series
of experiments the number of FoxP3-expressing Treg cells in
patients with UC which were clinically treated with vedolizumab
(ﬁgure 7). Clinical vedolizumab treatment resulted in an induc-
tion of FoxP3+ CD4+ Treg cells in the peripheral blood
already after the ﬁrst clinical infusion therapy (ﬁgure 7B, E).
This accumulation of Treg cells was associated with reduced
CD4+FoxP3− Teff cell numbers (ﬁgure 7C). Furthermore, a
signiﬁcant decrease of the ratio between Teff and Treg cells was
detected after one and two infusions in vedolizumab-treated
patients with UC (ﬁgure 7D) suggesting that α4β7 integrin
blockade markedly affects the balance between systemic Teff and
Treg cell responses in UC.
DISCUSSION
The role of T lymphocyte homing to the inﬂamed gut in the
pathogenesis of IBD is incompletely understood.13 23 48 This is
particularly true for Treg cells whose homing capacities to the
Figure 5 Continued
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Figure 6 Vedolizumab suppresses homing of human CD4+CD25− effector T (Teff ) and CD4+CD25+ regulatory T (Treg) cells from patients with UC but
not controls to the inﬂamed colon, while GPR15 knockdown only affects Teff cell homing. (A) Confocal in vivo imaging of homing of CFSE-labelled CD4
+CD25− Teff cells to the inﬂamed colon in dextran sodium sulfate (DSS)-treated NSG mice. While homing of these cells was augmented in mice given
UC-derived cells as compared with controls, treatment of NSG mice with vedolizumab inhibited homing of cells to the colon in patients with UC but not
controls. (B) FACS analysis of lamina propria cells from DSS-treated NSG mice in the presence or absence of Teff cell transfer from controls and
vedolizumab treatment as indicated. Left panels: Representative FACS analysis of CFSE+ human CD4+CD25− T cells from controls in the lamina propria of
DSS-treated NSG mice. Right panel: Quantitative analysis of homing of CFSE-labelled human CD4+CD25− T cells from controls to the inﬂamed colon in
DSS-treated NSG mice in the presence or absence of vedolizumab treatment (n=4). (C) FACS analysis of lamina propria cells from DSS-treated NSG mice in
the presence or absence of Teff cell transfer from patients with UC and vedolizumab treatment as indicated. Left panels: Representative FACS analysis of
CFSE+ human CD4+CD25− T cells from patients with UC in the lamina propria of DSS-treated NSG mice. Right panel: Quantitative analysis of homing of
CFSE-labelled CD4+CD25− T cells from patients with UC to the inﬂamed colon in DSS-treated NSG mice in the presence or absence of vedolizumab
treatment (n=4). (D) Left panel: CFSE+ human CD4+ T cells (n=3) were transfected with GPR15-speciﬁc siRNA followed by analysis of GPR15 mRNA
expression by PCR. Signiﬁcant differences in GPR15 expression upon transfection with siRNA1 and siRNA5 are indicated. Middle and right panels:
Representative images and FACS analysis of GFP positive T cells indicating successful transfer of siRNA into the T cells. (E) Quantitative analysis of GPR15
knockdown at the protein level. Upper panels: Representative FACS analysis. Lower panel: Quantitative analysis of GPR15 downregulation. (F) Confocal in
vivo imaging of homing of CD4+CD25− Teff cells to the inﬂamed colon in DSS-treated mice in the presence or absence of GPR15 knockdown. (G) FACS
analysis of lamina propria cells from DSS-treated NSG mice in the presence or absence of Teff cell transfer from patients with UC and GPR15 siRNA
treatment as indicated. Left panels: Representative FACS analysis of CFSE+ human CD4+CD25− Teff cells from patients with UC in the lamina propria of
DSS-treated NSG mice. Right panel: Quantitative analysis of homing of CFSE-labelled CD4+CD25− T cells from patients with UC to the inﬂamed colon in
DSS-treated NSG mice in the presence or absence of GPR15 siRNA treatment (n=3). (H) FACS analysis of lamina propria cells from DSS-treated NSG mice
after adoptive transfer of puriﬁed UC GPR15+ or GPR15− Treg and Teff cells as indicated. CD4+ cells from four patients with UC were pooled and sorted
by FACS. Tregs were deﬁned as CD4+CD25+ and Teffs as CD4+CD25−. (I) Confocal in vivo imaging of homing of CFSE-labelled Treg-enriched CD4+CD25
+ T cells to the inﬂamed colon in DSS-treated NSG mice. While homing of these cells was augmented in mice given UC-derived cells as compared with
controls, treatment of NSG mice with vedolizumab inhibited homing of cells to the colon in patients with UC but not controls. (J) FACS analysis of lamina
propria cells from DSS-treated NSG mice in the presence or absence of Treg cell transfer from controls and vedolizumab treatment as indicated. Left panels:
Representative FACS analysis of CFSE+ human CD4+CD25+ T cells from controls in the lamina propria of DSS-treated NSG mice. Right panel: Quantitative
analysis of homing of CFSE-labelled human Treg-enriched CD4+CD25+ T cells from controls to the inﬂamed colon in DSS-treated NSG mice in the
presence or absence of vedolizumab treatment (n=5). The control sample without cell transfer is from the same experiment as in 6B. (K) FACS analysis of
lamina propria cells from DSS-treated NSG mice in the presence or absence of Treg cell transfer from patients with UC and vedolizumab treatment as
indicated. Left panels: Representative FACS analysis of CFSE+ human CD4+CD25+ T cells from patients with UC in the lamina propria of DSS-treated NSG
mice. Right panel: Quantitative analysis of homing of CFSE-labelled Treg-enriched CD4+CD25+ T cells from patients with UC to the inﬂamed colon in
DSS-treated NSG mice (n=5). T cells from patients with UC were isolated and adoptively transferred to NSG mice in the presence or absence of
vedolizumab treatment. Lamina propria cells from NSG mice were then analysed by FACS analysis for CFSE+ cells. Signiﬁcant differences are indicated. (L)
FACS analysis of lamina propria cells from DSS-treated NSG mice in the presence or absence of Treg cell transfer from patients with UC and GPR15 siRNA
treatment as indicated. Left panels: Representative FACS analysis of CFSE+ human CD4+CD25+ T cells from patients with UC in the lamina propria of
DSS-treated NSG mice. Right panel: Quantitative analysis of homing of CFSE-labelled Treg-enriched CD4+CD25+ T cells from patients with UC to the
inﬂamed colon in DSS-treated NSG mice (n=3). T cells from patients with UC were isolated and adoptively transferred to NSG mice in the presence or
absence of GPR15 siRNA treatment. Lamina propria cells from NSG mice were then analysed by FACS analysis for CFSE+ cells.
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inﬂamed tissue are important for suppression of mucosal inﬂam-
mation29 and adoptive Treg transfer approaches in IBD.32 In the
present study, we assessed the homing capacities of human Treg
cells in patients with UC and compared the results with those of
Teff cells. By using a novel system to analyse homing of human
T cells in humanised NSG mice in vivo, we showed that UC Teff
cell homing is controlled by α4β7 and GPR15, while we
uncover an important regulatory role of α4β7 integrins rather
than GPR15 in controlling homing of UC Treg cells to the
inﬂamed gut. Our ﬁndings suggest new avenues for assessment
of gut homing in vivo by using humanised mouse models.
Initial studies revealed that expression of α4β7 was increased
on Treg cells in patients with UC as compared with controls.
This could be due to the effects of TGF-β1, a cytokine increas-
ingly present in the chronically inﬂamed mucosa in UC,49 as
this cytokine signiﬁcantly increased expression of α4β7 on Treg
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cells in the presence of the proinﬂammatory cytokines IL-6 and
IL-21. In contrast to Treg cells, however, expression of α4β7
was reduced on Teff cells in patients with UC as compared with
controls, although subsets of both cell types expressed α4β7 in
patients with UC.
Given the clinical success of the α4β7 neutralising antibody
vedolizumab for therapy of patients with UC,23 it was likely that
such antibody treatment would inhibit homing of Teff cells to
the human colon. However, the effects of such treatment on in
vivo homing of Treg cells remained largely unknown. To further
study the functional relevance of α4β7 for T cell homing in
vivo, we developed a new model for T cell analysis in immuno-
deﬁcient, humanised NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)
mice with experimental DSS colitis. Although this model could
not be used for analysis of human T cell homing after intraven-
ous administration, it was well suited to determine gut homing
upon cell transfer via the ileocolic artery. As NSG mice lack
murine B cells and T cells,37 this model excludes competition
between human and mouse lymphocytes for receptors on endo-
thelial cells. Moreover, this approach may prevent immune
reactions to the transferred cells by the absence of murine lym-
phocytes and NK cells. Finally, this system is suitable for analysis
of human T cell homing via α4β7, as human α4β7 has been pre-
viously shown to bind to murine MAdCAM-1 due to homolo-
gous integrin binding domains between murine and human
MAdCAM-1.46 This was conﬁrmed by our functional data
showing a high level of binding of α4β7 integrin on human
T cells to murine MAdCAM-1 as well as VCAM-1.
Our model differs in many aspects from a very recently
described model on assessment of T cell homing50 that used
intravenous injection of human T cells in a xenograft model by
implanting fetal small bowel tissue into C.B-17 SCID mice.
While this model has the potential advantage of allowing
homing of human T cells via human receptors to the xenograft,
it remains unclear how effective human T cells can escape from
lung capillaries in this model after intravenous transfer. In add-
ition, further information is needed how adoptive intravenous
transfer of human T cells leads to speciﬁc, efﬁcient homing to
the xenograft in the absence of vessel anastomosis. Therefore,
our model of T cell homing may hold signiﬁcant advantages for
Figure 7 Vedolizumab treatment of patients with UC results in increased numbers of regulatory T (Treg) cells in the peripheral blood. (A–C)
Patients with clinically active UC were treated intravenously with 300 mg vedolizumab at weeks 0, 2 and 6. Peripheral blood cells were isolated
before infusions and analysed for the number of CD4+ T cells (A), FoxP3+ Treg CD4+ cells (B) and FoxP3− Teff CD4+ cells (C) by FACS analysis.
Signiﬁcant differences are indicated. (D) Ratio between Teff cells and Treg cells in patients with UC upon vedolizumab therapy at weeks 0, 2 and
6. Signiﬁcant differences are indicated. (E) Representative FACS analysis of FoxP3+ Treg cells in peripheral blood in a patient with UC before and
after treatment with vedolizumab.
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quantitative assessment of human T cell homing to the inﬂamed
gut, although certain limitations exist as discussed above.
By studies in such humanised NSG mice we found that
homing of human Treg cells from healthy donors upon
intra-arterial injection is critically dependent on DSS treatment
probably due to DSS-induced upregulation of the α4β7 receptor
MAdCAM1 in the murine colon. Interestingly, vedolizumab
treatment did not affect homing of Teff cells or Treg cells from
controls to the inﬂamed gut in vivo. This ﬁnding suggests that
α4β7-dependent gut homing of T cells may be compensated by
other homing receptors such as CCR5, CCR9 or GPR15 in this
context. However, we detected a signiﬁcant induction of the
homing capacity of UC Treg cells as compared with Treg cells
from controls. Such augmented homing is likely due to upregu-
lation of α4β7 on Treg cells in UC, as vedolizumab treatment
signiﬁcantly suppressed UC Treg homing to the inﬂamed gut in
vivo. As expected from clinical observations, vedolizumab also
signiﬁcantly inhibited colonic homing of Teff cells from patients
with UC, although UC Teff cells expressed lower levels of α4β7
than control Teff cells.
These observations suggest that in vivo homing of Teff and
Treg cells in UC is critically dependent on α4β7 integrin expres-
sion. The augmented homing of Treg cells in UC may contribute
to the previously described reduction of blood Treg cells in UC
as well as to their accumulation in the mucosa in active
disease.29 In spite of the pronounced decline in Treg homing
caused by vedolizumab in our humanised mouse model, clinical
studies23 do not support the idea that vedolizumab-induced
reduction of Treg homing might lead to a negative effect on the
resolution of inﬂammation, possibly because it is more the
mucosal proportion of Treg and Teff cell populations than the
absolute number of Tregs, which is relevant in this context.29 51
Additionally, it is possible that Treg numbers in the inﬂamed gut
in UC are largely controlled by local differentiation and expan-
sion of inducible Tregs51 rather than by Treg homing.
Similarly to α4β7, GPR15 expression was upregulated on
Treg cells in UC. By using knockout mice this receptor had been
previously identiﬁed as a crucial regulator of homing of murine
Treg cells to the colon.33 Therefore, it appeared likely that
GPR15 would control homing of Treg cells to the inﬂamed
colon. As the ligand for GPR15 is not known, it was not pos-
sible to use an antibody with proven blockade of binding to its
ligand in our experiments. We therefore decided to use siRNA
knockdown, which induced a marked and signiﬁcant downregu-
lation of GPR15.
Unexpectedly, however, siRNA-mediated suppression of
GPR15 did not result in reduced homing of UC Treg cells to the
inﬂamed colon in humanised mice in vivo. The relevance of this
observation was highlighted by the ﬁnding that little or no
GPR15+ FoxP3+ regulatory T cells were noted by immunohis-
tochemistry in the inﬂamed colon of patients with UC. In con-
trast, homing of Teff cells from patients with UC with siRNA
knockdown of GPR15 was signiﬁcantly suppressed. Similarly to
our ﬁndings on MAdCAM-1, these results suggested that the
currently unknown GPR15 ligand is evolutionary conserved
between mice and humans. To our best knowledge, this is the
ﬁrst report of a functional relevance for GPR15 in colonic
homing of human UC Teff cells. Consistently, a recent study
could not detect GPR15 on colonic Treg cells in UC but showed
abundant GPR15 expression on mucosal Teff cells in UC.52
Collectively, these ﬁndings suggested that GPR15 expression is
not of crucial relevance for mediating UC Treg homing to the
inﬂamed gut in vivo. Although the reason for this observation
remains currently unclear, it is possible that GPR15-mediated
homing of human T cells requires co-receptors or additional
molecules that are not expressed on UC Treg cells. However,
these results propose GPR15 as an interesting therapeutic candi-
date for UC as the idea of selectively blocking Teff cell homing
to the colon holds promising perspectives.
Taken together, our ﬁndings uncover that α4β7 rather than
GPR15 appears to be crucial for gut homing of UC Treg cells,
while both adhesion molecules control homing of UC Teff cells.
In contrast to controls, vedolizumab treatment impaired gut
homing of Treg cells from patients with UC in humanised mice
in vivo. Consistently, clinical vedolizumab therapy led to Treg
accumulation in the peripheral blood in UC that may limit
expansion of Teff cells in the circulation and thereby favour sup-
pression of systemic inﬂammation in this disease.
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